Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) changed by 0.00% from its latest closing price compared to the recent 1-year high of $2.46. The company’s stock price has collected 3.64% of gains in the last five trading sessions. Press Release reported on 04/21/21 that Tonix Pharmaceuticals to Participate in Fourth Annual Neuroscience Innovation Forum
Is It Worth Investing in Tonix Pharmaceuticals Holding Corp. (NASDAQ :TNXP) Right Now?
Plus, the 36-month beta value for TNXP is at 1.35. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Tonix Pharmaceuticals Holding Corp. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $4.00. TNXP currently public float of 323.67M and currently shorts hold a 1.41% ratio of that float. Today, the average trading volume of TNXP was 29.18M shares.
TNXP’s Market Performance
TNXP stocks went up by 3.64% for the week, with a monthly drop of -6.56% and a quarterly performance of 17.71%, while its annual performance rate touched 63.79%. The volatility ratio for the week stands at 7.29% while the volatility levels for the past 30 days are set at 8.29% for Tonix Pharmaceuticals Holding Corp.. The simple moving average for the period of the last 20 days is 3.66% for TNXP stocks with a simple moving average of 18.94% for the last 200 days.
Analysts’ Opinion of TNXP
Many brokerage firms have already submitted their reports for TNXP stocks, with ROTH Capital repeating the rating for TNXP by listing it as a “Buy.” The predicted price for TNXP in the upcoming period, according to ROTH Capital is $4 based on the research report published on April 18th of the previous year 2019.
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $6. The rating they have provided for TNXP stocks is “Buy” according to the report published on August 18th, 2017.
TNXP Trading at -4.16% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.66% of loss for the given period.
Volatility was left at 8.29%, however, over the last 30 days, the volatility rate increased by 7.29%, as shares sank -5.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.72% lower at present.
During the last 5 trading sessions, TNXP rose by +3.64%, which changed the moving average for the period of 200-days by +79.25% in comparison to the 20-day moving average, which settled at $1.0968. In addition, Tonix Pharmaceuticals Holding Corp. saw 68.89% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at TNXP starting from LEDERMAN SETH, who purchase 16,733 shares at the price of $1.32 back on Mar 24. After this action, LEDERMAN SETH now owns 135,000 shares of Tonix Pharmaceuticals Holding Corp., valued at $22,088 using the latest closing price.
LEDERMAN SETH, the Chief Executive Officer of Tonix Pharmaceuticals Holding Corp., purchase 35,000 shares at $0.68 during a trade that took place back on Dec 30, which means that LEDERMAN SETH is holding 118,267 shares at $23,800 based on the most recent closing price.
Stock Fundamentals for TNXP
The total capital return value is set at -102.32, while invested capital returns managed to touch -103.21. Equity return is now at value -88.80, with -80.90 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp. (TNXP), the company’s capital structure generated 1.50 points at debt to equity in total, while total debt to capital is 1.47. Total debt to assets is 1.34, with long-term debt to equity ratio resting at 0.82. Finally, the long-term debt to capital ratio is 0.80.
The liquidity ratio also appears to be rather interesting for investors as it stands at 8.96.